

2023 Annual KPP Trend Report

-1.14% Overall Trend

Low Cost Generics & Clinical Innovation

By maximizing low-cost generics and implementing innovative clinical programs, our clients collectively achieved an industry leading overall trend.

6.93% Traditional Drug Trend

Generic Dispensing Rate 88.1%

• 7.1% Unit Price, 1.5% Utilization, 2.2% Drug Mix

-5.58% Specialty Drug Trend

Driving 50.4% of Total Plan Paid

• 10.3% Unit Cost, -0.9% Utilization, -3.9% Drug Mix

Innovative Clinical Programs

Clinical Performance Based Guarantee Suite of Clinical Programs that We Guarantee Will Lower Your Prescription Drug Spend

Rare Disease Care Rx

Ensures detailed review and personalized care for patients who need rare disease therapy

Adhere 90

Incentivizes members to fill 90-day supplies of maintenance medications to decrease copay and plan spend

Reference Based Pricing

Proactively contains cost by directing members to low cost alternatives in select drug classes

Top Drug Classes

Diabetes
Inflammatory Disease
Dermatology - Psoriasis/Eczema
Asthma & COPD
Neoplastic Disease

Forecast

Inflation Reduction Act

Future changes in drug list prices as price negotiations occur

Diabetes

Anticipate additional expanded indications to glucagon-like peptide agonsists and increased patient demand

Inflammatory

Expect increased uptake of adalimumab biosimilars with new strengths and interchangeability designations